https://clinicaltrials.gov/ct2/show/NCT02437110
He actually has experienced clinically measurable improvements. That's huge. Normally an ALS trial success consists of getting worse less quickly than before. Here, we're talking improvements.
I asked him if he knew if anyone else on the drug was having similar results. Unfortunately he was the only one he knew of on the drug protocol. NIH had a very small sample set and found very few HERV K positive people with ALS.
Isn't this the promise of precision medicine? To test the right therapy on the right patients? Why aren't we finding the right patients for this clinical trial with some urgency?
There are numerous, separate precision medicine projects in the ALS space. There are even more repositories of tissue of people with ALS. Cmon, folks, let's screen for HERV K and find some candidates and get this trial filled and completed quickly. Now!
It's not that hard if you really mean it when you say you collaborate.
No comments:
Post a Comment